Incyte Corp
NASDAQ:INCY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
51.18
83.38
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Incyte Corp
Incyte Corp
Other
Incyte Corp
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Incyte Corp
NASDAQ:INCY
|
Other
-$56.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-14%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other
-$100m
|
CAGR 3-Years
45%
|
CAGR 5-Years
22%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other
-$5.7B
|
CAGR 3-Years
-238%
|
CAGR 5-Years
-114%
|
CAGR 10-Years
-4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other
-$127m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other
-$398.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other
-$1.3B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
Incyte Corp
Glance View
Incyte Corporation, a biopharmaceutical company founded in 1991, has carved out a significant niche in the oncology and hematology sectors by focusing on the development and commercialization of innovative therapies. With a robust pipeline that includes targeted drugs and novel approaches to cancer treatment, Incyte has established its reputation as a leader in addressing challenging diseases. The company's flagship product, Jakafi, was the first FDA-approved therapy for myelofibrosis—a rare type of bone marrow cancer—and has since opened new avenues for treating various blood disorders. Investors will appreciate Incyte's strategic collaborations, like its partnership with Eli Lilly for the development of various compounds, which not only bolster its research pipeline but also diversify its revenue streams. As the company continues to expand its footprint in the biopharmaceutical landscape, Incyte is actively pursuing new indications for Jakafi and furthering its research into other key candidates. The firm is driven by a mission to transform cancer treatment, underpinned by strong clinical trial data and a commitment to innovation. Given the growing demand for effective cancer therapies, coupled with Incyte’s solid financial footing and ability to navigate the competitive landscape, the company presents an appealing opportunity for investors seeking exposure to the biotech sector. With a clear vision and a focus on unmet medical needs, Incyte stands poised to deliver sustained growth and long-term value in an evolving industry.
See Also
What is Incyte Corp's Other?
Other
-56.9m
USD
Based on the financial report for Sep 30, 2024, Incyte Corp's Other amounts to -56.9m USD.
What is Incyte Corp's Other growth rate?
Other CAGR 10Y
-14%
Over the last year, the Other growth was 14%. The average annual Other growth rates for Incyte Corp have been -29% over the past three years , -21% over the past five years , and -14% over the past ten years .
You don't have any saved screeners yet
